ClinicalTrials.gg
CompletedNCT04851964WAYPOINTUpdated Jan 27, 2026Results posted

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

A Phase 3 interventional study of Experimental: Tezepelumab and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by AstraZeneca. Completed at 112 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
416
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies in Nasal Polyps with a site in United States — 13 open to participants now, 20 under way, 8 of them phase 3. Nasal Polyps · United States.

Enrollment
5th of 71
416 · median 60
Started
2021
with 5 others
Phase 3
25 of 83
4 open now
Registered
51st of 83
by date
Lead sponsor
4 of 83
AstraZeneca

Among the 83 studies in Nasal Polyps with a site in United States, this one is the 5th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2021, is one of 25 in phase 3, and was the 51st registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

13 of the 83 studies in Nasal Polyps with a site in United States are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Nasal Polyps with a site in United States, or all of them as a file.
02

Study summary

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

Read the detailed description

This is a multicentre, randomised, double-blind, placebo controlled, parallel group study designed to evaluate the efficacy and safety of tezepelumab in adults with severe, chronic rhinosinusitis with nasal polyposis. Approximately 400 subjects will be randomized globally. Participants will receive tezepelumab, or placebo, administered via subcutaneous injection using the accessorized pre-filled syringe (APFS) every 4 weeks, over a 52-week treatment period. The study also includes a post-treatment follow-up period of 12-24 weeks for participants who complete the 52-week treatment period. All participants will have background mometasone furoate nasal spray or equivalent intranasal corticosteroid at a stable dose from Visit 1 and throughout the screening and study period.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps

Browse trials for

Keywords

  • Chronic rhinosinusitis with nasal polyps
  • Nasal polyps
  • Nasal polyposis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 that have:

    1. Severity consistent with need for surgery as defined by total NPS ≥ 5 (≥ 2 for each nostril) at screening, as determined by the central reader
    2. Nasal Congestion Score (NCS) ≥ 2 at Visit 1
    3. Ongoing documented NP symptoms over > 8 weeks prior to screening such as rhinorrhea and/or reduction/loss of smell
  2. SNOT-22 total score ≥ 30 at screening (Visit 1)
  3. Any standard of care for treatment of CRSwNP provided the participant is stable on that treatment for 30 days prior to Visit 1
  4. Documented treatment of nasal polyposis exacerbation with SCS for at least 3 consecutive days or one IM depo-injectable dose (or /intolerance to) within the past 12 months prior to Visit 1 but not within the last 3 months prior to Visit 1 and/or any history of NP surgery (or contraindications/intolerance to)

Exclusion criteria

Exclusion Criteria:

  1. Any comorbidities other than asthma (e.g. active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, primary ciliary dyskinesia, allergic bronchopulmonary mycosis, hypereosinophilic syndromes, etc.) that could confound interpretation of clinical efficacy results.
  2. Sinus surgery within 6 months of screening visit OR any sinus surgery in the past which changed the lateral wall of the nose making NPS evaluation impossible.
  3. Positive COVID-19 PCR test (or COVID-19 rapid test) or COVID-19 entry screening questionnaire during the screening visit. Evaluation will be based on on local standard of care as determined by current local guidelines.
  4. Regular use of decongestants (topical or systematic) at enrolment is not allowed unless used for endoscopic procedure
  5. Use of medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine, hydroxychloroquine, systemic or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1 and during the study period. Systemic corticosteroid use is defined as treatment with a burst of systemic corticosteroids for at least 3 consecutive days or a single IM depo-injectable dose of corticosteroids (considered equivalent to a 3-day burst of systemic corticosteroids).
  6. Receipt of COVID-19 vaccine (regardless of vaccine delivery platform) 28 days prior to date of IP administration at Visit 3 (randomisation visit).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
416 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab subcutaneous injection in an accessorized pre-filled syringe every 4 weeks (Q4W) added to background mometasone furoate (MFNS) or equivalent intranasal corticosteroid (INCS).

    Biological: Experimental: Tezepelumab · Drug: Mometasone furoate or equivalent intranasal corticosteroid

  • Placebo comparator
    Placebo

    Placebo subcutaneous injection in an accessorized pre-filled syringe Q4W added to background MFNS or equivalent INCS.

    Other: Placebo · Drug: Mometasone furoate or equivalent intranasal corticosteroid

Interventions

  • Tezepelumab subcutaneous injection

  • OtherPlacebo

    Placebo subcutaneous injection

  • DrugMometasone furoate or equivalent intranasal corticosteroid

    Background MFNS or equivalent INCS at stable dose

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total Nasal Polyp Score at Week 52

    The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.

    Time frame: Baseline to Week 52

  2. Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52

    The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.

    Time frame: Baseline to Week 52

Secondary outcomes

  1. Change From Baseline in Bi-weekly Mean Loss of Smell at Week 52

    Participant reported sense of smell will be evaluated as part of the NPSD. Loss of smell is captured by the DSS item (difficulty with sense of smell) in the NPSD asking participants to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses to the from Day -13 to Day 0. Bi-weekly (14-day) mean loss of smell will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.

    Time frame: Baseline to Week 52

  2. Change From Baseline in SinoNasal Outcome Test 22 (SNOT-22) at Week 52

    SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: Baseline to Week 52

  3. Change From Baseline in Lund Mackay Score Evaluated by CT at Week 52.

    The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).

    Time frame: Week 52

  4. Percentage of Participants With Nasal Polyp Surgery Decision and/or Systemic Corticosteroid for Nasal Polyposis up to Week 52

    Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Rescue treatment of NP is defined as requiring treatment with systemic corticosteroids (SCS) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids). Time to first NP surgery decision or SCS for NP = (date of the first NP surgery decision or start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.

    Time frame: Up to Week 52

  5. Percentage of Participants With Nasal Polyp Surgery Decision up to Week 52

    Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Time to first NP surgery decision = (date of the first NP surgery decision - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.

    Time frame: Up to Week 52

  6. Percentage of Participants With Systemic Corticosteroids for Nasal Polyposis up to Week 52

    Systemic corticosteroids (SCS) for nasal polyposis (NP) is defined as requiring at least 3 consecutive days (a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of SCS) for NP. Time to first SCS for NP = (start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.

    Time frame: Up to Week 52

  7. Change From Baseline in Bi-weekly Mean Nasal Polyposis Symptom Diary Total Symptom Score at Week 52

    The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 52

  8. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume (L) in 1 Second at Week 52.

    For participants with comorbid asthma and aspirin exacerbated respiratory disease (AERD)/nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NSAID-ERD), difference in change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) in the tezepelumab arm as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

    Time frame: Baseline to Week 52

Other outcomes

  1. Change From Baseline Over Time in Nasal Polyp Score Through Week 52.

    The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.

    Time frame: Baseline to Week 52

  2. Proportion of Participants With ≥1 Point Reduction in the Nasal Polyp Score at Week 52

    The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥1 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.

    Time frame: Baseline to Week 52

  3. Proportion of Participants With ≥2 Point Reduction in the Nasal Polyp Score at Week 52

    The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥2 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.

    Time frame: Baseline to Week 52

  4. Change From Baseline Over Time in Bi-weekly Mean Nasal Congestion Score Evaluated by Nasal Polyposis Symptom Diary Through Week 52.

    The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.

    Time frame: Baseline to Week 52

  5. Change From Baseline in Loss of Smell Evaluated by University of Pennsylvania Smell Identification Test (UPSIT) at Week 52.

    The University of Pennsylvania Smell Identification Test is a quantitative test of olfactory function which uses microencapsulated odorants that are released by scratching standardized odour-impregnated test booklets. Scores are based on number of correctly identified odours (score range 0-40, lower scores indicate poorer outcomes).

    Time frame: Baseline to Week 52

  6. Change From Baseline in Modified Lund Mackay Score Evaluated by CT at Week 52.

    The Modified Lund-Mackay score scoring system was used to provide a semi-quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) on each side were scored. Each sinus on each side was scored based on the percentage of opacification from mucosal thickening according to matrix: (score 0 for 0% Opacification; score 1 for 1-25% Opacification; score 2 for 26-50% Opacification; score 3 for 51-75% Opacification; score 4 for 76-99% Opacification; score 5 for 100% Opacification). The range of total Modified Lund Mackay score is from 0 to 50. Higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 52

  7. Change From Baseline in Sinus Severity Score by Quantitative CT Assessment at Week 52

    Quantitative assessment of sinus CT image data were used to derive an objective measure of sinus disease burden called sinus severity score. The sinus severity score is defined as: (sinus mucosal volume)/(sinus mucosal volume + sinus air volume)×100%. The range of sinus severity score is 0 to 100. Higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 52

  8. Exposure of Systemic Corticosteroids Over 52 Weeks

    The number of courses of SCS for NP per year was analysed using a negative binomial model. The response variable was the number of courses of SCS for NP received by a participant over the planned treatment period. The model included treatment group, baseline co-morbid asthma/AERD/NSAID-ERD status, prior NP surgery status, and region as factors. The logarithm of the time at risk (in years) was used as an offset variable, to adjust different follow-up times. Time during a course was not included in the calculation of time at risk.

    Time frame: Over 52 weeks

  9. Change From Baseline by Domain of the Nasal Polyposis Symptom Diary Through Week 52

    The participant will complete an 11-item nasal polyposis symptom diary each morning throughout the screening, treatment and follow-up periods. The participant is asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants are asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, and difficulty with sense of smell) and symptom impacts (difficulty with sleeping due to nasal symptoms and difficulty with daily activities due to nasal symptoms). Participants report the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe).

    Time frame: Baseline to Week 52

  10. Change From Baseline in Nasal Peak Inspiratory Flow Through Week 52.

    Nasal peak inspiratory flow evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.

    Time frame: Baseline to Week 52

  11. Change From Baseline in Asthma Control Questionnaire-6 at Week 52.

    The Asthma Control Questionnaire is an assessment of asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short acting beta-agonist use). Participants are asked to recall their level of asthma control during the previous week by responding to one bronchodilator use question and 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).

    Time frame: Baseline to Week 52

  12. Tezepelumab Pharmacokinetics

    Serum concentrations of tezepelumab through Week 64. Logarithm transformation was used when calculating geometric mean of serum concentrations. The results were transformed back to original scale.

    Time frame: Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, and Week 64

  13. Immunogenicity of Tezepelumab for Non-China Subjects

    Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.

    Time frame: Pre-dose samples at Baseline to Week 64

  14. Immunogenicity of Tezepelumab for China Subjects

    Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.

    Time frame: Pre-dose samples at Baseline to Week 64

07

Results

Posted Jan 27, 2026

Participant flow

A total of 416 participants were randomized, 6 of which were removed from analyses due to GCP issues, before study unblinding. The remaining 410 were randomized to either the treatment arm (204 participants) or placebo (206 participants) arms of the double-blind treatment period. Two participants were randomized but not dosed (one was withdrawal by subject, one did not meet inclusion/exclusion criteria). Therefore, 203 participants started in the treatment arm and 205 in the placebo arm.

Participant flow — Overall Study
MilestoneTezepelumabPlacebo
Started203205
Completed193174
Not completed1031
Withdrew: Death01
Withdrew: Lost to follow-up22
Withdrew: Withdrawal by subject823
Withdrew: Severe incompliance01
Withdrew: Nasal polyp surgery02
Withdrew: Other biologic treatment02

Outcome measures

PrimaryChange From Baseline in Total Nasal Polyp Score at Week 52

The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Total Nasal Polyp Score at Week 52
ScoreTezepelumabPlacebo
Change From Baseline in Total Nasal Polyp Score at Week 52-2.458 (-2.681 to -2.234)-0.380 (-0.611 to -0.148)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Difference in least squares means: -2.078 · 95% CI -2.399 to -1.757Model: Change from baseline in NPS = Treatment + Baseline co-morbid asthma/AERD/NSAID-ERD + Prior NP surgery + Region + Baseline NPS
PrimaryChange From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52

The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52
ScoreTezepelumabPlacebo
Change From Baseline in Bi-weekly Mean Nasal Congestion Score (NCS) at Week 52-1.743 (-1.864 to -1.622)-0.703 (-0.830 to -0.577)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Difference in least squares means: -1.039 · 95% CI -1.214 to -0.865Model: Change from baseline in bi-weekly mean NCS = Treatment + Baseline co-morbid asthma/AERD/NSAID-ERD + Prior NP surgery + Region + Baseline NCS
SecondaryChange From Baseline in Bi-weekly Mean Loss of Smell at Week 52

Participant reported sense of smell will be evaluated as part of the NPSD. Loss of smell is captured by the DSS item (difficulty with sense of smell) in the NPSD asking participants to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses to the from Day -13 to Day 0. Bi-weekly (14-day) mean loss of smell will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Bi-weekly Mean Loss of Smell at Week 52
ScoreTezepelumabPlacebo
Change From Baseline in Bi-weekly Mean Loss of Smell at Week 52-1.261 (-1.382 to -1.139)-0.255 (-0.378 to -0.133)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = <.0001 (The p-value is unadjusted, and is statistically significant at 0.01 level under multiple testing strategy.) · Difference in least squares means: -1.005 · 95% CI -1.177 to -0.834Change from baseline in bi-weekly mean loss of smell=Treatment+Baseline co-morbid asthma/AERD/NSAID-ERD+Prior NP surgery+Region+Baseline loss of smell
SecondaryChange From Baseline in SinoNasal Outcome Test 22 (SNOT-22) at Week 52

SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in SinoNasal Outcome Test 22 (SNOT-22) at Week 52
ScoreTezepelumabPlacebo
Change From Baseline in SinoNasal Outcome Test 22 (SNOT-22) at Week 52-45.022 (-48.572 to -41.472)-17.580 (-21.189 to -13.971)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Difference in least squares means: -27.441 · 95% CI -32.512 to -22.370Change from baseline in SNOT-22 = Treatment + Baseline co-morbid asthma/AERD/NSAID-ERD + Prior NP surgery + Region + Baseline SNOT-22 total score
SecondaryChange From Baseline in Lund Mackay Score Evaluated by CT at Week 52.

The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).

Time frame:
Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Lund Mackay Score Evaluated by CT at Week 52.
ScoreTezepelumabPlacebo
Change From Baseline in Lund Mackay Score Evaluated by CT at Week 52.-6.270 (-6.740 to -5.799)-0.569 (-1.046 to -0.093)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Difference in least squares means: -5.700 · 95% CI -6.371 to -5.030Change from baseline in LMK score = Treatment + Baseline co-morbid asthma/AERD/NSAID-ERD + Prior NP surgery + Region + Baseline LMK score
SecondaryPercentage of Participants With Nasal Polyp Surgery Decision and/or Systemic Corticosteroid for Nasal Polyposis up to Week 52

Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Rescue treatment of NP is defined as requiring treatment with systemic corticosteroids (SCS) for at least 3 consecutive days (a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids). Time to first NP surgery decision or SCS for NP = (date of the first NP surgery decision or start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Nasal Polyp Surgery Decision and/or Systemic Corticosteroid for Nasal Polyposis up to Week 52
Percentage of participantsTezepelumabPlacebo
Percentage of Participants With Nasal Polyp Surgery Decision and/or Systemic Corticosteroid for Nasal Polyposis up to Week 525.7 (1.3 to 15.0)31.4 (25.0 to 38.0)
Statistical analysis
  • Tezepelumab vs Placebo · Regression, Cox · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Hazard ratio (hr): 0.08 · 95% CI 0.03 to 0.16A hazard ratio less than 1 indicates a lower rate of incidence for subjects on Tezepelumab.
SecondaryPercentage of Participants With Nasal Polyp Surgery Decision up to Week 52

Surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g., polypectomy, endoscopic sinus surgery). Time to first NP surgery decision = (date of the first NP surgery decision - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Nasal Polyp Surgery Decision up to Week 52
Percentage of participantsTezepelumabPlacebo
Percentage of Participants With Nasal Polyp Surgery Decision up to Week 520.5 (0.0 to 2.5)22.0 (16.4 to 28.2)
Statistical analysis
  • Tezepelumab vs Placebo · Regression, Cox · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Hazard ratio (hr): 0.02 · 95% CI 0.00 to 0.09A hazard ratio less than 1 indicates a lower rate of incidence for subjects on Tezepelumab.
SecondaryPercentage of Participants With Systemic Corticosteroids for Nasal Polyposis up to Week 52

Systemic corticosteroids (SCS) for nasal polyposis (NP) is defined as requiring at least 3 consecutive days (a single depo-injectable dose of corticosteroids was considered equivalent to a 3-day course of SCS) for NP. Time to first SCS for NP = (start date of first SCS for NP use - date of randomisation)+1. Kaplan Meier estimates of percentage of participants with events and 95% confidence interval are provided for each treatment group.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Corticosteroids for Nasal Polyposis up to Week 52
Percentage of participantsTezepelumabPlacebo
Percentage of Participants With Systemic Corticosteroids for Nasal Polyposis up to Week 525.2 (1.1 to 14.7)19.3 (14.1 to 25.1)
Statistical analysis
  • Tezepelumab vs Placebo · Regression, Cox · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Hazard ratio (hr): 0.11 · 95% CI 0.04 to 0.25A hazard ratio less than 1 indicates a lower rate of incidence for subjects on Tezepelumab.
SecondaryChange From Baseline in Bi-weekly Mean Nasal Polyposis Symptom Diary Total Symptom Score at Week 52

The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Bi-weekly Mean Nasal Polyposis Symptom Diary Total Symptom Score at Week 52
ScoreTezepelumabPlacebo
Change From Baseline in Bi-weekly Mean Nasal Polyposis Symptom Diary Total Symptom Score at Week 52-10.388 (-11.174 to -9.601)-3.429 (-4.241 to -2.617)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = <.0001 (The p-value is unadjusted and it is statistically significant at 0.01 level under multiple testing strategy.) · Difference in least squares means: -6.959 · 95% CI -8.085 to -5.833Model: Change from baseline in NPSD TSS = Treatment + Baseline co-morbid asthma/AERD/NSAID-ERD + Prior NP surgery + Region + Baseline NPSD TSS
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume (L) in 1 Second at Week 52.

For participants with comorbid asthma and aspirin exacerbated respiratory disease (AERD)/nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NSAID-ERD), difference in change from baseline in pre-bronchodilator forced expiratory volume in 1 second (FEV1) in the tezepelumab arm as compared to placebo at Week 52. FEV1 is defined as the volume of air exhaled from the lungs in the first second of forced expiration.

Time frame:
Baseline to Week 52
Reported as:
Mean · Liter
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume (L) in 1 Second at Week 52.
LiterTezepelumabPlacebo
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume (L) in 1 Second at Week 52.0.022 (-0.065 to 0.108)0.027 (-0.055 to 0.108)
Statistical analysis
  • Tezepelumab vs Placebo · ANCOVA · p = 0.9362 (The p-value is unadjusted.) · Difference in least squares means: -0.005 · 95% CI -0.121 to 0.111Model: Change from baseline in pre-BD FEV1 = Treatment + Baseline co-morbid asthma/AERD/NSAID-ERD + Prior NP surgery + Region + Baseline pre-BD FEV1
Other pre-specifiedChange From Baseline Over Time in Nasal Polyp Score Through Week 52.

The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline Over Time in Nasal Polyp Score Through Week 52.
ScoreTezepelumabPlacebo
Week 4-1.615 (-1.797 to -1.433)-0.255 (-0.434 to -0.077)
Week 12-1.918 (-2.112 to -1.723)-0.376 (-0.569 to -0.182)
Week 24-2.104 (-2.310 to -1.899)-0.314 (-0.522 to -0.106)
Week 36-2.351 (-2.552 to -2.149)-0.287 (-0.493 to -0.082)
Week 52-2.458 (-2.681 to -2.234)-0.380 (-0.611 to -0.148)
Other pre-specifiedProportion of Participants With ≥1 Point Reduction in the Nasal Polyp Score at Week 52

The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥1 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Proportion of Participants With ≥1 Point Reduction in the Nasal Polyp Score at Week 52
ParticipantsTezepelumabPlacebo
Proportion of Participants With ≥1 Point Reduction in the Nasal Polyp Score at Week 5216164
Other pre-specifiedProportion of Participants With ≥2 Point Reduction in the Nasal Polyp Score at Week 52

The Nasal Polyp Score is the sum of the right and left nostril scores (maximum 8), as evaluated by nasal endoscopy. A participant with ≥2 point reduction in NPS at Week 52 in the absence of SCS for NP, biologic for NP, or NP surgery at or prior to that time point was defined as a responder, otherwise the participant was defined as a non-responder.

Time frame:
Baseline to Week 52
Reported as:
Count of participants · Participants
Proportion of Participants With ≥2 Point Reduction in the Nasal Polyp Score at Week 52
ParticipantsTezepelumabPlacebo
Proportion of Participants With ≥2 Point Reduction in the Nasal Polyp Score at Week 5212939
Other pre-specifiedChange From Baseline Over Time in Bi-weekly Mean Nasal Congestion Score Evaluated by Nasal Polyposis Symptom Diary Through Week 52.

The NCS is captured by one item in the NPSD (nasal polyps symptom diary) asking participants to rate the severity of their worst NC over the past 24 hours using the following response options: 0 - None; 1 - Mild; 2 - Moderate; 3 - Severe. Baseline will be the mean of daily responses from Day -13 to Day 0. Bi-weekly (14-day) mean NCS will be calculated if at least 8 days in each 14-day period has evaluable data; otherwise the bi-weekly mean is set to missing.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline Over Time in Bi-weekly Mean Nasal Congestion Score Evaluated by Nasal Polyposis Symptom Diary Through Week 52.
ScoreTezepelumabPlacebo
Week 2-0.379 (-0.438 to -0.319)-0.192 (-0.251 to -0.133)
Week 4-0.779 (-0.868 to -0.691)-0.322 (-0.411 to -0.234)
Week 8-1.134 (-1.236 to -1.032)-0.451 (-0.553 to -0.349)
Week 12-1.270 (-1.376 to -1.164)-0.607 (-0.714 to -0.500)
Week 24-1.515 (-1.628 to -1.402)-0.703 (-0.818 to -0.588)
Week 36-1.629 (-1.748 to -1.509)-0.726 (-0.850 to -0.601)
Week 48-1.735 (-1.856 to -1.613)-0.721 (-0.847 to -0.594)
Week 52-1.743 (-1.864 to -1.622)-0.703 (-0.830 to -0.577)
Other pre-specifiedChange From Baseline in Loss of Smell Evaluated by University of Pennsylvania Smell Identification Test (UPSIT) at Week 52.

The University of Pennsylvania Smell Identification Test is a quantitative test of olfactory function which uses microencapsulated odorants that are released by scratching standardized odour-impregnated test booklets. Scores are based on number of correctly identified odours (score range 0-40, lower scores indicate poorer outcomes).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Loss of Smell Evaluated by University of Pennsylvania Smell Identification Test (UPSIT) at Week 52.
ScoreTezepelumabPlacebo
Change From Baseline in Loss of Smell Evaluated by University of Pennsylvania Smell Identification Test (UPSIT) at Week 52.9.310 (8.147 to 10.474)-0.192 (-1.378 to 0.993)
Other pre-specifiedChange From Baseline in Modified Lund Mackay Score Evaluated by CT at Week 52.

The Modified Lund-Mackay score scoring system was used to provide a semi-quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid, and frontal) on each side were scored. Each sinus on each side was scored based on the percentage of opacification from mucosal thickening according to matrix: (score 0 for 0% Opacification; score 1 for 1-25% Opacification; score 2 for 26-50% Opacification; score 3 for 51-75% Opacification; score 4 for 76-99% Opacification; score 5 for 100% Opacification). The range of total Modified Lund Mackay score is from 0 to 50. Higher scores indicate greater symptom severity.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Modified Lund Mackay Score Evaluated by CT at Week 52.
ScoreTezepelumabPlacebo
Change From Baseline in Modified Lund Mackay Score Evaluated by CT at Week 52.-17.520 (-18.708 to -16.332)-1.106 (-2.291 to 0.078)
Other pre-specifiedChange From Baseline in Sinus Severity Score by Quantitative CT Assessment at Week 52

Quantitative assessment of sinus CT image data were used to derive an objective measure of sinus disease burden called sinus severity score. The sinus severity score is defined as: (sinus mucosal volume)/(sinus mucosal volume + sinus air volume)×100%. The range of sinus severity score is 0 to 100. Higher scores indicate greater symptom severity.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Sinus Severity Score by Quantitative CT Assessment at Week 52
ScoreTezepelumabPlacebo
Change From Baseline in Sinus Severity Score by Quantitative CT Assessment at Week 52-32.754 (-35.047 to -30.461)-1.978 (-4.267 to 0.310)
Other pre-specifiedExposure of Systemic Corticosteroids Over 52 Weeks

The number of courses of SCS for NP per year was analysed using a negative binomial model. The response variable was the number of courses of SCS for NP received by a participant over the planned treatment period. The model included treatment group, baseline co-morbid asthma/AERD/NSAID-ERD status, prior NP surgery status, and region as factors. The logarithm of the time at risk (in years) was used as an offset variable, to adjust different follow-up times. Time during a course was not included in the calculation of time at risk.

Time frame:
Over 52 weeks
Reported as:
Least squares mean · SCS courses per year
Exposure of Systemic Corticosteroids Over 52 Weeks
SCS courses per yearTezepelumabPlacebo
Exposure of Systemic Corticosteroids Over 52 Weeks0.04 (0.02 to 0.08)0.35 (0.23 to 0.55)
Other pre-specifiedChange From Baseline by Domain of the Nasal Polyposis Symptom Diary Through Week 52

The participant will complete an 11-item nasal polyposis symptom diary each morning throughout the screening, treatment and follow-up periods. The participant is asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants are asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, and difficulty with sense of smell) and symptom impacts (difficulty with sleeping due to nasal symptoms and difficulty with daily activities due to nasal symptoms). Participants report the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline by Domain of the Nasal Polyposis Symptom Diary Through Week 52
ScoreTezepelumabPlacebo
Nasal Blockage Week 2-0.359 (-0.416 to -0.301)-0.170 (-0.227 to -0.112)
Nasal Blockage Week 4-0.744 (-0.831 to -0.656)-0.298 (-0.385 to -0.211)
Nasal Blockage Week 8-1.122 (-1.225 to -1.018)-0.423 (-0.527 to -0.320)
Nasal Blockage Week 12-1.259 (-1.367 to -1.152)-0.555 (-0.663 to -0.447)
Nasal Blockage Week 24-1.502 (-1.617 to -1.387)-0.678 (-0.795 to -0.561)
Nasal Blockage Week 36-1.628 (-1.750 to -1.506)-0.703 (-0.830 to -0.576)
Nasal Blockage Week 48-1.697 (-1.821 to -1.573)-0.722 (-0.850 to -0.594)
Nasal Blockage Week 52-1.759 (-1.882 to -1.636)-0.697 (-0.825 to -0.569)
Nasal Congestion Week 2-0.379 (-0.438 to -0.319)-0.192 (-0.251 to -0.133)
Nasal Congestion Week 4-0.779 (-0.868 to -0.691)-0.322 (-0.411 to -0.234)
Nasal Congestion Week 8-1.134 (-1.236 to -1.032)-0.451 (-0.553 to -0.349)
Nasal Congestion Week 12-1.270 (-1.376 to -1.164)-0.607 (-0.714 to -0.500)
Nasal Congestion Week 24-1.515 (-1.628 to -1.402)-0.703 (-0.818 to -0.588)
Nasal Congestion Week 36-1.629 (-1.748 to -1.509)-0.726 (-0.850 to -0.601)
Nasal Congestion Week 48-1.735 (-1.856 to -1.613)-0.721 (-0.847 to -0.594)
Nasal Congestion Week 52-1.743 (-1.864 to -1.622)-0.703 (-0.830 to -0.577)
Runny Nose Week 2-0.347 (-0.407 to -0.288)-0.164 (-0.224 to -0.105)
Runny Nose Week 4-0.676 (-0.757 to -0.595)-0.239 (-0.320 to -0.158)
Runny Nose Week 8-0.966 (-1.056 to -0.875)-0.360 (-0.450 to -0.270)
Runny Nose Week 12-1.075 (-1.173 to -0.976)-0.467 (-0.566 to -0.369)
Runny Nose Week 24-1.258 (-1.363 to -1.153)-0.464 (-0.571 to -0.358)
Runny Nose Week 36-1.353 (-1.466 to -1.240)-0.467 (-0.583 to -0.351)
Runny Nose Week 48-1.448 (-1.561 to -1.336)-0.410 (-0.528 to -0.292)
Runny Nose Week 52-1.429 (-1.545 to -1.313)-0.400 (-0.523 to -0.277)
Postnasal Drip Week 2-0.252 (-0.310 to -0.195)-0.153 (-0.210 to -0.096)
Postnasal Drip Week 4-0.552 (-0.633 to -0.472)-0.230 (-0.310 to -0.150)
Postnasal Drip Week 8-0.806 (-0.898 to -0.715)-0.336 (-0.428 to -0.244)
Postnasal Drip Week 12-0.916 (-1.015 to -0.816)-0.388 (-0.488 to -0.288)
Postnasal Drip Week 24-1.084 (-1.194 to -0.974)-0.418 (-0.529 to -0.306)
Postnasal Drip Week 36-1.175 (-1.290 to -1.061)-0.441 (-0.559 to -0.322)
Postnasal Drip Week 48-1.189 (-1.307 to -1.071)-0.376 (-0.498 to -0.253)
Postnasal Drip Week 52-1.177 (-1.294 to -1.060)-0.348 (-0.471 to -0.225)
Headache Week 2-0.259 (-0.318 to -0.199)-0.185 (-0.245 to -0.126)
Headache Week 4-0.414 (-0.489 to -0.340)-0.294 (-0.369 to -0.220)
Headache Week 8-0.673 (-0.753 to -0.594)-0.382 (-0.461 to -0.303)
Headache Week 12-0.753 (-0.842 to -0.665)-0.439 (-0.528 to -0.350)
Headache Week 24-0.870 (-0.970 to -0.771)-0.470 (-0.571 to -0.369)
Headache Week 36-0.928 (-1.034 to -0.821)-0.387 (-0.496 to -0.278)
Headache Week 48-0.962 (-1.075 to -0.849)-0.361 (-0.476 to -0.245)
Headache Week 52-0.941 (-1.056 to -0.825)-0.341 (-0.459 to -0.222)
Facial Pain Week 2-0.250 (-0.310 to -0.190)-0.171 (-0.231 to -0.111)
Facial Pain Week 4-0.438 (-0.514 to -0.363)-0.276 (-0.352 to -0.201)
Facial Pain Week 8-0.723 (-0.806 to -0.640)-0.368 (-0.450 to -0.285)
Facial Pain Week 12-0.801 (-0.888 to -0.713)-0.438 (-0.526 to -0.350)
Facial Pain Week 24-0.957 (-1.056 to -0.858)-0.494 (-0.594 to -0.393)
Facial Pain Week 36-1.000 (-1.106 to -0.893)-0.396 (-0.506 to -0.286)
Facial Pain Week 48-1.010 (-1.125 to -0.895)-0.358 (-0.476 to -0.239)
Facial Pain Week 52-1.002 (-1.118 to -0.886)-0.316 (-0.436 to -0.197)
Facial Pressure Week 2-0.276 (-0.338 to -0.215)-0.170 (-0.232 to -0.109)
Facial Pressure Week 4-0.509 (-0.587 to -0.431)-0.277 (-0.355 to -0.199)
Facial Pressure Week 8-0.778 (-0.866 to -0.689)-0.373 (-0.461 to -0.284)
Facial Pressure Week 12-0.840 (-0.929 to -0.750)-0.460 (-0.549 to -0.370)
Facial Pressure Week 24-0.987 (-1.087 to -0.887)-0.501 (-0.603 to -0.400)
Facial Pressure Week 36-1.039 (-1.148 to -0.930)-0.400 (-0.512 to -0.288)
Facial Pressure Week 48-1.093 (-1.210 to -0.975)-0.379 (-0.499 to -0.258)
Facial Pressure Week 52-1.081 (-1.200 to -0.962)-0.342 (-0.464 to -0.220)
Difficulty with Sense of Smell Week 2-0.126 (-0.164 to -0.088)-0.037 (-0.074 to 0.001)
Difficulty with Sense of Smell Week 4-0.416 (-0.483 to -0.348)-0.053 (-0.120 to 0.014)
Difficulty with Sense of Smell Week 8-0.804 (-0.897 to -0.711)-0.107 (-0.200 to -0.015)
Difficulty with Sense of Smell Week 12-0.909 (-1.015 to -0.804)-0.208 (-0.313 to -0.103)
Difficulty with Sense of Smell Week 24-1.078 (-1.195 to -0.961)-0.275 (-0.392 to -0.158)
Difficulty with Sense of Smell Week 36-1.101 (-1.221 to -0.980)-0.300 (-0.422 to -0.177)
Difficulty with Sense of Smell Week 48-1.242 (-1.364 to -1.121)-0.289 (-0.413 to -0.166)
Difficulty with Sense of Smell Week 52-1.261 (-1.382 to -1.139)-0.255 (-0.378 to -0.133)
Difficulty with Sleeping Week 2-0.340 (-0.399 to -0.281)-0.188 (-0.247 to -0.129)
Difficulty with Sleeping Week 4-0.655 (-0.738 to -0.572)-0.284 (-0.367 to -0.202)
Difficulty with Sleeping Week 8-0.994 (-1.084 to -0.904)-0.454 (-0.544 to -0.364)
Difficulty with Sleeping Week 12-1.081 (-1.177 to -0.984)-0.495 (-0.591 to -0.398)
Difficulty with Sleeping Week 24-1.262 (-1.365 to -1.159)-0.516 (-0.621 to -0.411)
Difficulty with Sleeping Week 36-1.307 (-1.420 to -1.194)-0.520 (-0.637 to -0.403)
Difficulty with Sleeping Week 48-1.307 (-1.427 to -1.188)-0.469 (-0.595 to -0.342)
Difficulty with Sleeping Week 52-1.317 (-1.436 to -1.197)-0.454 (-0.580 to -0.327)
Difficulty with Daily Activities week 2-0.282 (-0.340 to -0.225)-0.183 (-0.240 to -0.126)
Difficulty with Daily Activities week 4-0.504 (-0.582 to -0.425)-0.294 (-0.372 to -0.216)
Difficulty with Daily Activities week 8-0.836 (-0.926 to -0.747)-0.408 (-0.497 to -0.319)
Difficulty with Daily Activities week 12-0.948 (-1.043 to -0.853)-0.469 (-0.564 to -0.374)
Difficulty with Daily Activities week 24-1.135 (-1.242 to -1.028)-0.520 (-0.628 to -0.412)
Difficulty with Daily Activities week 36-1.201 (-1.316 to -1.085)-0.509 (-0.629 to -0.389)
Difficulty with Daily Activities week 48-1.213 (-1.334 to -1.091)-0.440 (-0.568 to -0.313)
Difficulty with Daily Activities week 52-1.212 (-1.334 to -1.090)-0.414 (-0.542 to -0.285)
Other pre-specifiedChange From Baseline in Nasal Peak Inspiratory Flow Through Week 52.

Nasal peak inspiratory flow evaluation represents a physiologic measure of the air flow through both nasal cavities during forced inspiration expressed in liters per minute.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Liters per minute.
Change From Baseline in Nasal Peak Inspiratory Flow Through Week 52.
Liters per minute.TezepelumabPlacebo
Week 1221.860 (10.888 to 32.831)-1.695 (-12.313 to 8.923)
Week 2429.437 (17.500 to 41.373)6.258 (-5.563 to 18.080)
Week 3611.228 (0.875 to 21.581)-4.941 (-15.570 to 5.687)
Week 5222.551 (11.467 to 33.635)0.489 (-10.973 to 11.952)
Other pre-specifiedChange From Baseline in Asthma Control Questionnaire-6 at Week 52.

The Asthma Control Questionnaire is an assessment of asthma symptoms (nighttime waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and short acting beta-agonist use). Participants are asked to recall their level of asthma control during the previous week by responding to one bronchodilator use question and 5 symptom questions. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score
Change From Baseline in Asthma Control Questionnaire-6 at Week 52.
ScoreTezepelumabPlacebo
Change From Baseline in Asthma Control Questionnaire-6 at Week 52.-1.203 (-1.334 to -1.072)-0.815 (-0.967 to -0.663)
Other pre-specifiedTezepelumab Pharmacokinetics

Serum concentrations of tezepelumab through Week 64. Logarithm transformation was used when calculating geometric mean of serum concentrations. The results were transformed back to original scale.

Time frame:
Pre-dose samples at Baseline, Week 4, Week 12, Week 24, Week 36, Week 52, and Week 64
Reported as:
Geometric mean · μg/mL
Tezepelumab Pharmacokinetics
μg/mLTezepelumabPlacebo
BaselineNA ± NA—
Week 412.165 ± 35.9—
Week 1221.496 ± 40.8—
Week 2423.994 ± 43.0—
Week 3625.237 ± 45.4—
Week 5224.352 ± 43.7—
Week 642.449 ± 103.1—
Other pre-specifiedImmunogenicity of Tezepelumab for Non-China Subjects

Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.

Time frame:
Pre-dose samples at Baseline to Week 64
Reported as:
Number · Participants
Immunogenicity of Tezepelumab for Non-China Subjects
ParticipantsTezepelumabPlacebo
ADA prevalence1019
ADA positive at baseline only21
Treatment-induced ADA positive612
Treatment-boosted ADA positive00
Treatment emergent ADA (ADA incidence)612
Both baseline and at least one post-baseline ADA positive24
ADA persistently positive411
ADA transiently positive47
TE-ADA positive with maximum titre > median of maximum titres12
ADA positive at baseline (regardless of post-baseline)42
Any post-baseline ADA positive818
nAb positive at baseline and/or post-baseline (nAb prevalence)22
Treatment-induced nAb positive (nAb incidence)12
Other pre-specifiedImmunogenicity of Tezepelumab for China Subjects

Anti-drug antibodies (ADA) responses at baseline and post-baseline. ADA prevalence was defined as patients who are ADA positive at any time including baseline. Persistently positive was defined as having at least two post-baseline ADA positive measurements (with ≥16 weeks between first and last positive) or an ADA positive result at the last available post-baseline assessment. Transiently positive was defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. Treatment boosted ADA was defined as baseline positive ADA titre that was boosted to a 4-fold or higher-level following treatment. Treatment emergent ADA (ADA incidence) was defined as the sum of treatment induced ADA and treatment boosted ADA.

Time frame:
Pre-dose samples at Baseline to Week 64
Reported as:
Number · Participants
Immunogenicity of Tezepelumab for China Subjects
ParticipantsTezepelumabPlacebo
ADA prevalence34
ADA positive at baseline only10
Treatment-induced ADA positive23
Treatment-boosted ADA positive00
Treatment emergent ADA (ADA incidence)23
Both baseline and at least one post-baseline ADA positive01
ADA persistently positive12
ADA transiently positive12
TE-ADA positive with maximum titre > median of maximum titres10
ADA positive at baseline (regardless of post-baseline)11
Any post-baseline ADA positive24
nAb positive at baseline and/or post-baseline (nAb prevalence)10
Treatment-induced nAb positive (nAb incidence)10

Adverse events

Collected over From visit 1 (the date of the first study procedure) until end of study up to week 76.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-in Period0/408 (0%)0/408 (0%)20/408 (4.9%)
Tezepelumab0/203 (0%)11/203 (5.4%)119/203 (58.6%)
Placebo1/205 (0.5%)14/205 (6.8%)119/205 (58%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventRun-in PeriodTezepelumabPlacebo
AsthmaRespiratory, thoracic and mediastinal disorders0/4080/2032/205
AppendicitisInfections and infestations0/4081/2030/205
Arthritis bacterialInfections and infestations0/4081/2030/205
COVID-19 pneumoniaInfections and infestations0/4081/2030/205
Escherichia urinary tract infectionInfections and infestations0/4081/2030/205
Pneumonia bacterialInfections and infestations0/4081/2030/205
Pulmonary tuberculosisInfections and infestations0/4081/2030/205
Femur fractureInjury, poisoning and procedural complications0/4081/2030/205
Invasive lobular breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4081/2030/205
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4081/2030/205
Most frequent other events
Most frequent other events
EventRun-in PeriodTezepelumabPlacebo
Chronic rhinosinusitis with nasal polypsRespiratory, thoracic and mediastinal disorders1/40816/20356/205
COVID-19Infections and infestations1/40855/20344/205
NasopharyngitisInfections and infestations4/40845/20323/205
Upper respiratory tract infectionInfections and infestations1/40823/20313/205
HeadacheNervous system disorders11/40819/20316/205
EpistaxisRespiratory, thoracic and mediastinal disorders1/40814/2037/205
AsthmaRespiratory, thoracic and mediastinal disorders1/4081/20312/205
PharyngitisInfections and infestations0/40811/2031/205

Baseline characteristics

All participants who were randomized and received any IP were included in the full analysis set.

Age, Categorical
Age, Categorical(Participants)TezepelumabPlaceboTotal
<=18 years000
Between 18 and 65 years174179353
>=65 years292655
Age, Continuous
Age, Continuous(years)TezepelumabPlaceboTotal
Mean50.1 ± 13.6049.4 ± 13.6949.7 ± 13.63
Sex: Female, Male
Sex: Female, Male(Participants)TezepelumabPlaceboTotal
Female7765142
Male126140266
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TezepelumabPlaceboTotal
Hispanic or Latino111122
Not Hispanic or Latino192194386
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TezepelumabPlaceboTotal
Black or African American336
White150149299
Native Hawaiian or other Pacific Islander000
American Indian or Alaska Native000
Asian465197
Other426
Not reported000
08

Study locations

112 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Walnut Creek, California 94598, United States
  • Research Site
    Colorado Springs, Colorado 80923, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Boca Raton, Florida 33487, United States
  • Research Site
    Chicago, Illinois 60657, United States
  • Research Site
    Baltimore, Maryland 21224, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Columbia, Missouri 65212, United States
  • Research Site
    New York, New York 10003, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    North Charleston, South Carolina 29406, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Norfolk, Virginia 23507, United States
  • Research Site
    Spokane, Washington 99201, United States
  • Research Site
    Milwaukee, Wisconsin 53228, United States
  • Research Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Research Site
    Hamilton, Ontario L8S 1G5, Canada
  • Research Site
    London, Ontario N6A 4V2, Canada
  • Research Site
    Montreal, Quebec H2V 2K1, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Québec, Quebec G1S 4L8, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Québec, Quebec G1V 4W2, Canada
  • Research Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Research Site
    Bengbu, 233004, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310014, China
  • Research Site
    Hengyang, 421001, China
  • Research Site
    Lanzhou, 730030, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210009, China
  • Research Site
    Qingdao, 266011, China
  • Research Site
    Shanghai, 200031, China
  • Research Site
    Shanghai, 200433, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Taizhou, 225300, China
  • Research Site
    Tianjin, 300121, China
  • Research Site
    Tianjin, 300211, China
  • Research Site
    Wenzhou, 325027, China
  • Research Site
    Wuhan, 430060, China
  • Research Site
    Xi'an, 710068, China
  • Research Site
    Yinchuan, 750001, China
  • Research Site
    Zunyi, 563100, China
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Aarhus N, 8200, Denmark
  • Research Site
    Hillerød, 3400, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    København NV, 2400, Denmark
  • Research Site
    Køge, 4600, Denmark
  • Research Site
    Odense, 5000, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Berlin, 10629, Germany
  • Research Site
    Berlin, 13353, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Heidelberg, 69120, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    Marburg, 35043, Germany
  • Research Site
    Tübingen, 72076, Germany
  • Research Site
    Wiesbaden, 65183, Germany
  • Research Site
    Budapest, 1046, Hungary
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1134, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Pécs, 7621, Hungary
  • Research Site
    Siófok, 8600, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Bunkyō City, 113-8431, Japan
  • Research Site
    Chuo-shi, 409-3898, Japan
  • Research Site
    Habikino-shi, 583-0886, Japan
  • Research Site
    Ichikawa-shi, 272-0111, Japan
  • Research Site
    Itabashi-ku, 173-8610, Japan
  • Research Site
    Kashiwa-shi, 277-0882, Japan
  • Research Site
    Kisarazu-shi, 292-8535, Japan
  • Research Site
    Miyazaki, 880-8510, Japan
  • Research Site
    Nagaoka-shi, 940-8621, Japan
  • Research Site
    Nerima-ku, 177-0035, Japan
  • Research Site
    Niigata, 951-8520, Japan
  • Research Site
    Osaka, 553-0003, Japan
  • Research Site
    Saitama-shi, 336-8522, Japan
  • Research Site
    Sapporo, 003-0022, Japan
  • Research Site
    Sendai, 983-8512, Japan
  • Research Site
    Suwa-shi, 392-8510, Japan
  • Research Site
    Toyonaka Shi, 560-0082, Japan
  • Research Site
    Yokohama, 227-8501, Japan
  • Research Site
    Yokohama, 236-0037, Japan
  • Research Site
    Bialystok, 15-879, Poland
  • Research Site
    Bydgoszcz, 85-231, Poland
  • Research Site
    Krakow, 31-513, Poland
  • Research Site
    Nadarzyn, 05-830, Poland
  • Research Site
    Wroclaw, 50-556, Poland
  • Research Site
    Wroclaw, 53-301, Poland

Showing the first 100 of 112 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Lipworth BJ, Han JK, Desrosiers M, Hopkins C, Lee SE, Mullol J, Pfaar O, Li T, Chen C, Almqvist G, Margolis MK, McLaren J, Jagadeesh S, MacKay J, Megally A, Hellqvist A, Mankad VS, Bahadori L, Ponnarambil SS; WAYPOINT Study Investigators. Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2025 Mar 27;392(12):1178-1188. doi: 10.1056/NEJMoa2414482. Epub 2025 Mar 1. PubMed 40106374 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Sep 2024, 41 months.

Results were first posted in Jan 2026, 1 year 4 months after primary completion.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 41 months is above that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2021
First posted
Apr 21, 2021
StartActual
Apr 22, 2021
Primary completionActual
Sep 23, 2024
CompletionActual
Dec 11, 2024
Results first posted
Jan 27, 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04851964
Lead sponsor
AstraZeneca
Collaborators
Amgen
Responsible party
Sponsor
First posted
Apr 21, 2021
Start date
Apr 22, 2021
Primary completion
Sep 23, 2024
Completion
Dec 11, 2024
Results posted
Jan 27, 2026
Last update
Jan 27, 2026

Study contacts

Brian Lipworth, MD
principal investigator · University of Dundee
Joseph K Han, MD
principal investigator · Eastern Virginia Medical School

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion